Publication: Heterogeneous immunoreactivity of frozen human benign and malignant breast lesions
to C-MYC and C-Ha-ras cellular oncogenes
Authors
pechoux, C. ; Chardonnet, Y. ; Chignol, M.C. ; Noël, P.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
C-myc and c-Ha-ras oncoprotein expression
was studied by immunohistochemistry and gene
detection by in situ hybridization on serial frozen
sections of 32 breast lesions (19 benign biopsies and 13
infiltrating carcinomas). C-myc protein was expressed in
15/19 benign and 12/13 malignant lesions; c-myc gene
was detected in 17/19 benign and 13/13 malignant
lesions. Although a higher proportion of benign biopsies
(819) showed more than 50% of protein-positive cells
than malignant specimens, this cannot predict the
outcome of a lesion. Conversely, p2 1 ras protein was
expressed only in 2/19 benign lesions and in most cases
of grade 1 to 111 carcinomas. The c-Ha-ras gene was
always detected in a small percentage of cells, in both
benign and malignant lesions. The results obtained with
atypical hyperplasia, a doubtful proliferating lesion,
suggests that p21 c-Ha-ras protein expression is not
restricted to breast carcinomas.
Although Southern blot is commonly considered as a
very sensitive technique for oncogene analysis, no
amplification of c-myc and c-Ha-ras gene has been
demonstrated either in benign or malignant lesions. The
detection, on serial frozen sections, of proteins and DNA
of c-myc and c-Ha-ras, showed a possible amplification
of the c-myc and c-Ha-ras genes in various benign and
malignant lesions.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.